Biology of Cerebral Arteriovenous Malformations and Prognosis of Cerebral Arteriovenous Malformations

Fondation Ophtalmologique Adolphe de Rothschild300 enrolled

Overview

The cerebral arteriovenous malformations correspond to the formation of an entanglement of morphologically abnormal vessels called nidus, which shunt the blood circulation directly from the arterial circulation to the venous circulation. The cerebral arteriovenous malformations are an important cause of hemorrhagic stroke. The hypothesis is that cerebral haemorrhage associated with a cerebral arteriovenous malformations would come from peri-nidal micro-vessels, in connection with infiltration of leucocytes and / or defective maintenance of microvascular integrity by platelets.

Study Type

OBSERVATIONAL

Enrollment

300

Conditions

Cerebral Arteriovenous Malformations Ruptured or Unruptured Cerebral Arteriovenous Malformations

Eligibility

Sex: ALLMin age: 0 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient over 18 years old * Patient with a cerebral AVM for which an intervention (endovascular treatment or surgery) or only clinical monitoring * Express consent to participate in the study And * children * Free informed and express consent of both holders of the minor patient's parental authority, or, by way of derogation and only if the other holder of parental authority cannot give his or her consent within a time limit compatible with the methodological requirements specific to the conduct of the research with regard to its purposes, of one of the two holders of parental authority Exclusion Criteria: * Patient benefiting from a legal protection measure * Pregnant or breast feeding woman

Outcomes

Primary Outcomes

Associaton between dosage of endothelial marker and the arteriovenous malformation pronostic

associaton between dosage of endothelial marker in blood samples and correlation with clinical outcome

Time frame: 6 months

Associaton between dosage of platelet and the arteriovenous malformation pronostic

Dosage of platelet in blood samples and correlation with clinical outcome

Time frame: 6 months

Associaton between dosage of neutrophilic and the arteriovenous malformation pronostic

Dosage of neutrophilic in blood samples and correlation with clinical outcome

Time frame: 6 months

Associaton between neo-angiogenesis activation markers and the arteriovenous malformation pronostic

Dosage neo-angiogenesis activation markers in blood samples and correlation with clinical outcome

Time frame: 6 months

Biology of Cerebral Arteriovenous Malformations and Prognosis of Cerebral Arteriovenous Malformations

Overview

Conditions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Central Contacts